| Objective: To assess the effectiveness of bisphosphonates for decreasingperiprosthetic bone resorption after THA.Methods: We searched Pubmed, Embase, OVID, CBM, and the CochraneLibrary, hand searching of reference lists of all the selected articles. Weincluded randomized controlled trials of bisphosphonates administration inpatients underwent THA and had bone density or biochemical markers of boneturnover outcomes. Two reviewers independently extracted data and assessedquality. All data analyses were performed by the Cochrane Collaboration’sRevMan5.1.Results: We included16studies involving827patients underwent THA,424were randomized to receive bisphosphonates and403to placebo or nomedication. Bone resorption in BPs group was significantly less than that incontrol group at3and12months postoperatively, respectively [(MD=0.04,95%CI (0.02,0.07), P=0.002);(MD=0.06,95%CI (0.03,0.09), P=0.0004);respectively]. And bone resorption in BPs group was still less than that incontrol group at6month, the result bordered on significance [MD=0.03,95%CI(-0.00,0.06), P=0.05]. There was a trend towards a less bone resorption in BPs group than in control group at24to36months (MD=0.04,95%CI (-0.03,0.11),P=0.23) or at48to72months (MD=0.07,95%CI (-0.00,0.14), P=0.06),although it did not reach statically significance. Both BAP and NTX-I weresignificantly suppressed by bisphosphonates at6and12months (p＜0.05).Conclusions: In conclusion, BPs therapy is beneficial in decreasing earlyphase of periprosthetic bone loss in patients underwent THA. However, thelong-term effectiveness of BPs is still not confirmed. Further investigations withprolong follow-up and clinical outcomes are needed. |
PDF Full Text Request